Editorial
doi: 10.1002/hep.21892.
New therapies for hepatitis C
- PMID: 17879364
- DOI: 10.1002/hep.21892
Item in Clipboard
Editorial
New therapies for hepatitis C
Hepatology.
2007 Sep.
No abstract available
Comment on
-
Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients.Hepatology. 2007 Sep;46(3):631-9. doi: 10.1002/hep.21781. Hepatology. 2007. PMID: 17680654 Clinical Trial.
-
Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.Hepatology. 2007 Sep;46(3):640-8. doi: 10.1002/hep.21774. Hepatology. 2007. PMID: 17879366 Clinical Trial.
Similar articles
-
[Introduction].Enferm Infecc Microbiol Clin. 2013 Jul;31 Suppl 3:1. doi: 10.1016/S0213-005X(13)70116-2. Enferm Infecc Microbiol Clin. 2013. PMID: 24063895 Spanish. No abstract available.
-
[Victrelis and Incivek against hepatitis C: some promising options].Perspect Infirm. 2012 Jan-Feb;9(1):58-9. Perspect Infirm. 2012. PMID: 22295460 French. No abstract available.
-
Future therapies for hepatitis C: where do we go from here?Nat Clin Pract Gastroenterol Hepatol. 2007 Feb;4(2):60-1. doi: 10.1038/ncpgasthep0736. Nat Clin Pract Gastroenterol Hepatol. 2007. PMID: 17268539 No abstract available.
-
[New drugs for hepatitis C].Duodecim. 2014;130(18):1813-22. Duodecim. 2014. PMID: 25558623 Review. Finnish.
-
New pharmacotherapy for hepatitis C.Clin Pharmacol Ther. 2012 Sep;92(3):294-305. doi: 10.1038/clpt.2012.103. Epub 2012 Aug 1. Clin Pharmacol Ther. 2012. PMID: 22850602 Review.
Cited by
-
Targeting HCV entry for development of therapeutics.Viruses. 2010 Aug;2(8):1718-1733. doi: 10.3390/v2081718. Epub 2010 Aug 18. Viruses. 2010. PMID: 21994703 Free PMC article.
-
Hepatitis C protease and polymerase inhibitors in development.AIDS Patient Care STDS. 2008 Jun;22(6):449-57. doi: 10.1089/apc.2007.0199. AIDS Patient Care STDS. 2008. PMID: 18479202 Free PMC article. Review.
-
Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.Antimicrob Agents Chemother. 2009 Mar;53(3):967-76. doi: 10.1128/AAC.00939-08. Epub 2008 Dec 22. Antimicrob Agents Chemother. 2009. PMID: 19104013 Free PMC article.
-
Extended-therapy duration for chronic hepatitis C, genotype 1: the long and the short of it.World J Gastroenterol. 2008 Jun 21;14(23):3621-7. doi: 10.3748/wjg.14.3621. World J Gastroenterol. 2008. PMID: 18595128 Free PMC article. Review.
-
Modulation of hepatitis C virus RNA abundance and the isoprenoid biosynthesis pathway by microRNA miR-122 involves distinct mechanisms.J Virol. 2010 Jan;84(1):666-70. doi: 10.1128/JVI.01156-09. J Virol. 2010. PMID: 19846523 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical